Pharmacogenetics is the study of how genetic variations influence a person's response to drugs – and ultimately contribute to reduced efficacy and adverse drug reactions. Up to 90% of the variability in drug response between individuals can be explained by genetics.1 Pharmacogenetic information is now included in the labeling of about 10% of drugs approved by the FDA.2
Inherited variants in the cytochrome P450 drug metabolism genes contribute significantly to an individual's drug response. Three of the most clinically important CYP450 drug metabolizing enzymes are CYP2C9, CYP2C19, and CYP2D6. Together, these three enzymes metabolize up to 40% of all currently prescribed drugs.3
| DNA Direct’s Drug Metabolism Enzyme Panel: |
|
Testing for a panel of genetic variants in each of these CYP450 genes allows us to predict if a person will have impaired or increased metabolism of drugs processed by these enzymes. This knowledge can help you individualize drug selection and dosing based on your patient's genetic make-up.
1. Wijnen PA, Op den Buijsch RA, Drent M, et al. The prevalence and clinical relevance of cytochrome P450 polymorphisms. Aliment Pharmacol Ther. 2007;26 Suppl 2:211-9.2. U.S. Food and Drug Administration. Table of Valid Genomic Biomarkers in the Context of Approved Drug Labels. Updated April 07, 2008. Available at: http://www.fda.gov/cder/genomics/genomic_biomarkers_table.htm. Accessed July 28, 2008.
3. Blue Cross Blue Shield Association. Special Report Genotyping for CYP450 polymorphisms to determine drug metabolizer status. Technology Assessment Program. 2004;19(9).